Kimberly Stegmaier, M.D.
Kimberly Stegmaier, an Institute Member of the Broad Institute of MIT and Harvard, has advanced the application of genomics to drug and protein target discovery. She is a member of the Cancer Program, where she serves on the Cancer Program Steering Committee and is an active collaborator with numerous programs and platforms at Broad Institute.
The Stegmaier laboratory develops and integrates “omic” approaches to identify new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. The laboratory has focused on pediatric malignancies notable for the aberrancy of differentiation and/or oncogenic activation of transcription factors: the acute leukemias, neuroblastoma, and Ewing sarcoma. The laboratory has applied an integrative chemical and functional genomic approach to two primary avenues of investigation in childhood malignancy: the discovery of modulators of biological state switches, such as differentiation, and the modulation of aberrant transcription factors.
Stegmaier is also an associate professor of pediatrics at Harvard Medical School and a principal investigator at Dana-Farber Cancer Institute (DFCI). She is the co-director of the Pediatric Hematologic Malignancy Program and an attending physician providing clinical care in Pediatric Oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital. At a national level, she is a strong advocate for pediatric cancer research, serving as a council member with the Society for Pediatric Research (SPR) and a steering committee member with the AACR Pediatric Cancer Working Group. She has won numerous awards, including the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, the SPR Young Investigator Award, the Sir William Osler Young Investigator Award from the Interurban Clinical Club, and a SU2C Innovative Research Grant.
Stegmaier received her undergraduate degree from Duke University and her medical degree from Harvard Medical School, and trained in Pediatrics and Pediatric Hematology/Oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute. She completed her postdoctoral training at the Dana-Farber Cancer Institute and with Todd Golub at Broad Institute, where she focused on the development of new gene expression-based approaches to small molecule discovery.